HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Licenses OTC And Cosmetics Portfolio To Trimb In Scandinavia

Executive Summary

Trimb has gained the exclusive rights from Teva to market across Scandinavia a portfolio of "well-known" consumer health brands, covering skin-care, oral-care, and digestive health, as well as dietary supplements. 

You may also be interested in...



Karo Pharma Acquires Nordic OTCs From Teva

Generics giant Teva has divested a portfolio of OTC brands marketed in the Nordics to Sweden's Karo, which has been distributing the products in the region for the past 18 months.

Teva Divests US OTC Store Brand Portfolio to PL Developments

Israel's Teva has trimmed its OTC portfolio by offloading its US store brands to PL Developments.

Karo Grabs Sweden’s Trimb To Grow Presence In Nordics

Karo’s new private-equity owners have flexed their muscles to snap up Sweden’s Trimb in a move which will expand the company’s reach in the Nordics and beyond.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel